Doctors Note Logo

Published on: 9/23/2026

Is the RSV vaccine a one-time shot?

For most adults, the RSV vaccine is currently given as a single lifetime dose, and the CDC does not recommend annual or repeat doses at this time. Protection has been shown to last through at least two to three RSV seasons, which is why revaccination is not advised even if several years have passed. There are important exceptions, including pregnancy, where a dose is recommended during each pregnancy, and infants, who may receive a protective antibody shot rather than a vaccine each season. Timing, age eligibility, and risk factors all change what applies to you, so there are several details to consider below. See the complete answer below before assuming one shot covers you for life.

Because RSV symptoms overlap heavily with colds, flu, and COVID-19, it can be hard to know whether what you are feeling is minor or worth urgent attention, especially if you are over 50, pregnant, or caring for an infant. Taking a few minutes to complete a free, instant, online symptom check can help you organize your symptoms, understand possible causes, and decide whether to monitor at home or contact a clinician next.

Last reviewed for medical accuracy: 09/23/2025

answer background

Explanation

Is the RSV Vaccine a One-Time Shot?

Respiratory syncytial virus (RSV) causes seasonal winter respiratory illness in infants, older adults and pregnant people. You may be asking: is the RSV vaccine a one time shot? The short answer is that most current RSV vaccines are given as a single dose per season or per pregnancy. Below, we break down who needs which dose, when, and why.


What Is RSV and Who’s at Risk?

Respiratory syncytial virus (RSV) can cause everything from a mild cold to serious lung infections like bronchiolitis or pneumonia.

  • Infants under 6 months – biggest risk for hospitalization
  • Older adults (60 years and up) – increased risk of severe disease
  • Pregnant people – passive protection to baby
  • People with chronic heart or lung disease, weakened immunity

Unvaccinated people in these groups are more likely to need hospital care. Vaccination helps reduce severe RSV infection.


Types of RSV Vaccines and Doses

Today’s FDA-approved RSV preventive products fall into two main categories:

  1. Adult/adolescent RSV vaccines
    • Arexvy (GSK) – for ages 60+
    • Abrysvo (Pfizer) – for ages 60+ and maternal immunization

  2. Monoclonal antibody for infants
    • Nirsevimab (Beyfortus) – for infants under 8 months at season start or under 19 months with risk factors

Adult/Adolescent RSV Vaccines

  • Who: Anyone 60 years and older
  • Dose: A single intramuscular injection (0.5 mL)
  • Timing: Given before RSV season (fall/winter)
  • Repeat? We don’t yet know if booster doses will be needed each season. Current guidance is one dose per season, pending more research.

Maternal RSV Vaccine

  • Who: Pregnant people 32–36 weeks gestation
  • Dose: One dose during every pregnancy
  • Benefit: Antibodies cross the placenta, protecting baby for the first few months of life
  • Repeat? One shot per pregnancy; you can get it again if you become pregnant another season.

Infant Monoclonal Antibody (Nirsevimab)

  • Who: Infants < 8 months at RSV season start or < 19 months with conditions like chronic lung disease
  • Dose: Single dose before or shortly after RSV season begins
  • Protection: Passive immunity for the season
  • Repeat? One dose per RSV season.

Is the RSV Vaccine a One-Time Shot?

  • For older adults and adolescents, RSV vaccination is one dose per season.
  • For pregnant people, it’s one dose per pregnancy (typically 32–36 weeks gestation).
  • For infants at high risk, the monoclonal antibody is one dose each season.

Bottom line: You don’t get a lifetime “one and done” RSV shot—current guidance is a single dose for each RSV season or pregnancy. Future studies will tell us if annual boosters are needed, similar to flu shots.


Why One Dose per Season?

  • RSV seasons recur annually, usually in fall through early spring.
  • Immunity from a single dose appears strong enough to cover one season in older adults and infants.
  • Pregnant people receive protection for their baby’s first critical months.

As data accumulates, recommendations may evolve. Stay tuned to the CDC and FDA for updates.


Benefits vs. Possible Side Effects

Benefits

  • Reduces hospitalizations for severe RSV disease
  • Lessens symptoms like wheezing, difficulty breathing and dehydration
  • Protects infants through maternal antibodies or monoclonal antibodies

Side Effects

Side effects are generally mild and short-lived:

  • Injection site soreness, redness or swelling
  • Fatigue, headache, muscle pain
  • Occasionally mild fever

Serious allergic reactions are rare. Always report any concerns to your healthcare provider.


Questions to Ask Your Doctor

  • “Am I or my baby eligible for an RSV vaccine this season?”
  • “When is the best time to schedule my shot?”
  • “Are there any specific health conditions we should watch for?”
  • “What symptoms warrant a follow-up visit or emergency care?”

If you ever feel unwell or notice severe breathing problems, chest pain, high fever or confusion, speak to a doctor immediately, as these could be signs of a serious condition.


Monitor Your Symptoms at Home

Not sure if your cough or fever is RSV or something else? Try a free, online symptom check, using the doctor approved Ubie Symptom Checker to help guide your next steps. It’s quick, confidential and doctor-designed.


Key Takeaways

  • “Is the RSV vaccine a one time shot?”
    • Yes – one dose per season for older adults and infants, one dose per pregnancy for maternal protection.
  • Current vaccines and monoclonal antibodies are designed for seasonal protection.
  • Future guidance on annual boosters may change as more data emerges.
  • Side effects are usually mild; serious reactions are rare.
  • Always speak to a doctor about life-threatening or serious symptoms.

Stay informed through reliable sources like the CDC, FDA and your healthcare provider. Preventive care, including timely RSV vaccination, is one of the best tools to protect you and your loved ones each season.

(References)

  • * Chu HY, Englund JA. Maternal immunization. Birth Defects Res. 2017 Mar 15;109(5):379-386. doi: 10.1002/bdra.23547. PMID: 28398678.

  • * Qiu X, Xu S, Lu Y, Luo Z, Yan Y, Wang C, Ji J. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53. doi: 10.1016/j.cytogfr.2022.10.001. Epub 2022 Oct 13. PMID: 36280532.

  • * Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. PMID: 36791160.

  • * Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL, ConquerRSV Study Group. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. PMID: 38091530.

  • * Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669.

  • * Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1. Epub 2024 Aug 15. PMID: 39146277.

  • * Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 study group. Efficacy, safety, and immunogenicity of the AS01(E)-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14. PMID: 40245915.

  • * Paes BA, Bacchini F, Bracht M, Rodgers-Gray B, Carbonell-Estrany X. Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. Hum Vaccin Immunother. 2025 Dec;21(1):2521920. doi: 10.1080/21645515.2025.2521920. Epub 2025 Jun 24. PMID: 40555690; PMCID: PMC12785216.

  • * Surie D, Self WH, Yuengling KA, Lauring AS, Zhu Y, Safdar B, Ginde AA, Simon SJ, Peltan ID, Brown SM, Gaglani M, Ghamande S, Columbus C, Mohr NM, Gibbs KW, Hager DN, Prekker M, Gong MN, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Gordon AJ, Qadir N, Chang SY, Mallow C, Felzer JR, Kwon JH, Exline MC, Vaughn IA, Ramesh M, Papalambros L, Mosier JM, Harris ES, Baughman A, Cornelison SA, Blair PW, Johnson CA, Lewis NM, Ellington S, Grijalva CG, Talbot HK, Casey JD, Halasa N, Chappell JD, Rutkowski RE, Ma KC, Dawood FS, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025 Oct 28;334(16):1442-1451. doi: 10.1001/jama.2025.15896. PMID: 40884491; PMCID: PMC12398767.

  • * Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.